Visit the company's website:
With an increasing focus on the healthcare sector, we now offer medical devices, surgical robots and planning software for use in stereotactic neurosurgery for procedures including Deep Brain Stimulation (DBS), Motor Cortex Stimulation (MCS), Stereo Electro-Encephalography (SEEG), neuro-endoscopy, radio-surgery, biopsy and Transcranial Magnetic Stimulation (TMS).
We have also entered the field of medical diagnostics with the creation of Renishaw Diagnostics Ltd, which aims to become the premier provider of automated multiplex diagnostic and clinical research systems for fast, reliable and simplified disease detection.
AMBS - Most undervalued bio-tech in the market. Read the recent Yahoo news.
Expected to announce a deal soon with Becton Dickinson for its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market.
Company's patented drug, MANF, could be the blockbuster drug of the 21st century. Due diligence.
Current market cap: $29M
Under a dime a share currently.
Follow the company on Twitter: @AmarantusBio .... 8,542 followers
There's no better stokc to own right now than AMBS. It's substantially undervalued with tremendous upside both short and long term.
Could easily gain 500% or more before the end of the year.
Go with what you know.
"No additional funding required".
FB is a stock that you invest in for when you retire at 65.
AMBS is a stock that you invest in now so that you can retire many years earlier.
You missed the low on Thursday. Shorts and the penny flippers will buy on any dips. Shorts to cover and penny flippers to re buy their positions.
This is one p.r. away from .15 or higher.
the months ahead.
At this critical time in the Company’s life cycle, and in the face of a potentially catastrophic government shutdown and pending default on the United States creditworthiness, both management and the Board felt it was important to further strengthen our balance sheet. We saw what happened to the capital markets and capital raising in the summer of 2011 when there was a similar partisan government showdown in Washington, and we do not intend to allow such events to potentially interfere with the important work we are doing as we seek to bring products that could potentially assist in reducing the overall cost of care while simultaneously improving patient outcomes. We believe we have somewhat fortified the Company and its shareholders from this untenable, yet worryingly routine set of circumstances.
Internally, we are focused on taking key fundamental value-building steps to advance LymPro towards commercialization, projected for the second half of 2014. We are also reprioritizing our pipeline for MANF as new data is gathered in various orphan indications and planning the critical path to first-in-man studies. As we move these programs forward, the funds raised gives the Company the necessary resources to attract the key management talent necessary to actualize these plans and further lend credibility to our programs by having proven teams executing them. As data continues to flow in, we believe we will be in a position to fundamentally improve shareholder value in the coming months and ultimately put the Company in a position to up-list to a national exchange.
The Board of Directors and Management are now working closely together to improve the corporate governance at the Board and management levels, as well as the financial controls within the Company, in order to meet the requirements of a national stock exchange listing. We expect to take concrete steps in this direction in the coming months that will be communicated to the marketplace.
In closing, we continue to make progress in advancing our programs forward, we have the capital resources to weather significant risk in the capital markets, we believe that if we execute on our plans we could be in a position to up-list to a national exchange without the need to raise additional capital, and the Board of Directors and management are working to position the Company for this important corporate milestone. We are continually looking for ways to improve our company and intend to maintain an open dialogue with our shareholders as we move forward in our mission.
Thank you for taking the time to read this blog and I look forward to continuing to communicate with you as we move forward.
President & CEO
Today's C.E.O. blog:
Over the last 12 months, Amarantus has achieved significant growth as we continue to pursue our business plan of bringing meaningful products to market for human ailments associated with neurodegeneration and apoptosis. In doing so, we have identified exciting new potential uses for our patented therapeutic MANF in orphan indications and have also expanded into diagnostics with the in-license of LymPro Test ® for Alzheimer’s disease and the acquisition of the NuroPro Blood Test for Parkinson’s disease.
This morning, we announced the second closing of a previously announced private placement offering bringing total proceeds to $3 million. Importantly, if Amarantus shares trade above $0.10 for a period of time, the Company has the option to call the warrants with the potential to yield an additional $5 million to the Company. Taken together, this could yield a total of $8 million to the Company and significantly improve the Company’s balance sheet, potentially allowing Amarantus to reach the financial listing standards necessary to up-list to a national stock exchange. Existing and new investors in this offering were accompanied by members of our Board of Advisors, Board of Directors and Company Management, emphasizing our belief in the business plan and the path forward the Company is on. The offering will yield proceeds sufficient for the Company to move its MANF and LymPro programs forward, while giving management the necessary resources to execute a business development strategy to bolster the fundamental value of our therapeutics and diagnostics divisions while improving the Company’s position in various negotiations. Additionally, we have begun to pursue an aggressive non-dilutive funding program with the recent appointment of our Director of Sponsored Research F. Randall Grimes, which we are hopeful will yield additional capital to fund core and non-core programs in t